Julie Kim is president of the US Business Unit, US Country Head, and member of the executive team at Takeda. The US Business Unit portfolio encompasses gastroenterology, neuroscience, plasma-derived therapies, and rare diseases. Kim joined Takeda in 2019 through the acquisition of Shire. At Takeda, she became president of the Plasma-Derived Therapies Business Unit until April 2022, when she took on her current role. Kim’s 30-year health care career has included global, regional, country, and functional leadership positions spanning therapeutic areas, international market access, country and regional general management, marketing, and emerging market development. Kim was named one of Boston’s 50 Most Influential Asian American Pacific Islanders in 2023 and included on the 2022 PharmaVoice 100 list and Fierce Pharma’s list of 2020’s Fiercest Women in Life Sciences. (Takeda is a 2023 Festival Underwriter)
Previously
Eighty percent of what impacts our health happens outside of the doctor's office: from education and employment opportunities to access to housing, transportation, and quality...